Duc Viet Pham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Duc Viet Pham has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Arnim Quante
Charité - University Medicine Berlin, Campus Benjamin Franklin, Department of Psychiatry and Psychotherapy, Berlin, Germany
2 shared publications
Latest Publications
- Open Access
- 23 March 2026
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
- Vol. 40 (1) , 3-16
Treatment Options for Sleep Disturbances in Dementia: A Systematic Review
Objective: This systematic review aims to evaluate recent evidence on interventions for sleep disturbances in dementia, a major clinical concern, with limited pharmacological and non-pharmacological strategies examined in controlled trials. Methods: We included eight RCTs (N = 666 participants; 2020 – January 2025) in people with dementia and sleep disturbances. Records were identified via MEDLINE, screened using PRISMA-guidelines, and non-randomized or non-intervention studies were excluded. Risk-of-bias was assessed with Cochrane RoB2, and effect sizes (Cohen’s d) were calculated in R. Results: Z-drugs indicated small-large benefits, with eszopiclone significantly improving sleep efficiency and latency. Orexin receptor antagonists indicated mixed evidence, with low-dose lemborexant (2.5 mg) most favorable, meeting benchmarks for nocturnal awakenings. Circadian modulation light therapy was associated with reduced nocturnal awakenings in small trials, while relaxation-based music therapy indicated little to no effect. Social stimulation with PARO indicated increased sleep time and large positive effects on sleep efficiency, despite missing clinical benchmarks. Conclusions: Evidence is limited by sparse reporting and few trials per intervention. Z-drug eszopiclone, low-dose ORA lemborexant, and social stimulation PARO show the most favorable profile across outcomes and benchmarks, but pharmacological options require careful risk–benefit consideration. Non-pharmacological approaches appear safer but under-researched. Future trials should standardize outcomes and tailor strategies to patient needs. No external funding. The review was registered in INPLASY: https://doi.org/10.37766/inplasy2025.1.0097 .
- 23 March 2026
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
- Vol. 40 (1) , 3-16
Open AccessTreatment Options for Sleep Disturbances in Dementia: A Systematic Review
Objective: This systematic review aims to evaluate recent evidence on interventions for sleep disturbances in dementia, a major clinical concern, with limited pharmacological and non-pharmacological strategies examined in controlled trials. Methods: We included eight RCTs (N = 666 participants; 2020 – January 2025) in people with dementia and sleep disturbances. Records were identified via MEDLINE, screened using PRISMA-guidelines, and non-randomized or non-intervention studies were excluded. Risk-of-bias was assessed with Cochrane RoB2, and effect sizes (Cohen’s d) were calculated in R. Results: Z-drugs indicated small-large benefits, with eszopiclone significantly improving sleep efficiency and latency. Orexin receptor antagonists indicated mixed evidence, with low-dose lemborexant (2.5 mg) most favorable, meeting benchmarks for nocturnal awakenings. Circadian modulation light therapy was associated with reduced nocturnal awakenings in small trials, while relaxation-based music therapy indicated little to no effect. Social stimulation with PARO indicated increased sleep time and large positive effects on sleep efficiency, despite missing clinical benchmarks. Conclusions: Evidence is limited by sparse reporting and few trials per intervention. Z-drug eszopiclone, low-dose ORA lemborexant, and social stimulation PARO show the most favorable profile across outcomes and benchmarks, but pharmacological options require careful risk–benefit consideration. Non-pharmacological approaches appear safer but under-researched. Future trials should standardize outcomes and tailor strategies to patient needs. No external funding. The review was registered in INPLASY: https://doi.org/10.37766/inplasy2025.1.0097 .
- 23 January 2025
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Current state of therapies for sleep disturbances in dementia - a systematic review
INPLASY202510097 Current state of therapies for sleep disturbances in dementia – a systematic review Keywords: Sleep disturbances in dementia; insomnia in Alzheimer’s disease; pharmacol…
- 23 January 2025
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Current state of therapies for sleep disturbances in dementia - a systematic review
INPLASY202510097 Current state of therapies for sleep disturbances in dementia – a systematic review Keywords: Sleep disturbances in dementia; insomnia in Alzheimer’s disease; pharmacol…